J. Merola

发表

Clinical validation of digital biomarkers and machine learning models for remote measurement of psoriasis and psoriatic arthritis

A. Ogdie, L. Mangravite, L. Omberg, 2022, medRxiv.

OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial

O. FitzGerald, J. Merola, T. Hendrikx, 2017 .

83 Biib059, a monoclonal antibody targeting bdca2, demonstrates evidence of proof of biological activity in subjects with cutaneous lupus

B. Werneburg, J. Merola, R. Furie, 2017, Lupus Science & Medicine.

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

A. Gottlieb, R. Burge, A. Menter, 2018, The British journal of dermatology.

Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

P. Foley, J. Merola, K. See, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus

J. Merola, J. Merola, K. Costenbader, 2014, Lupus.

Clinical manifestations and survival among adults with (SLE) according to age at diagnosis

E. Karlson, P. Schur, B. Lu, 2014, Lupus.

OP0112 In psoriatic arthritis fatigue is driven by inflammation, disease duration, and chronic pain: an observational danbio registry study

L. Coates, J. Merola, L. Dreyer, 2017, The Journal of rheumatology.

SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le

B. Werneburg, J. Merola, L. Stevenson, 2017 .

SAT0461 Characterisation of different low disease activity measurements in patients with psoriatic arthritis

J. Merola, A. Gottlieb, L. Aikman, 2017 .

AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

J. Merola, E. Rampakakis, W. Boehncke, 2023, Annals of the Rheumatic Diseases.